You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》博安生物-B(06955.HK)今起招股 一手入場費3,999.92元
綠葉製藥(02186.HK)分拆的綜合性生物製藥商博安生物-B(06955.HK)公布,擬全球發售約1,069.48萬股,香港公開發售佔約一成,國際發售佔約九成。每股招股價19.8元。該股今日(19日)起招股,周四(22日)中午截止,預期下周五(30日)掛牌。每手200股,一手入場費3,999.92元。聯席保薦人為瑞銀集團及安信國際。 公司上市引入3名基石投資者,包括艾迪藥業(688488.SH)創辦人傅和亮、Harvest及中生製藥(01177.HK),認購約1.5億元公司股份。 此外,公司上市料淨集資近1.53億元,當中約59.5%將用於核心產品的研發;約31.4%用於管線中其他產品的研發;約6.1%用於商業化目的;約3%用於營運資金及其他一般企業用途。 綠葉製藥指出,倘博安生物全球發售得以進行,博安生物H股的市值將約為100.84億元,緊隨全球發售完成後,公司將透過其全資附屬間接控制博安生物股本約70.81%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account